-- Shenzhen Salubris Pharmaceuticals' (SHE:002294) subsidiary, Salubris Biotherapeutics, presented the positive effects of the JK06 at the American Association for Cancer Research, according to a Shenzhen bourse filing on Monday.
The drug was tested for metastatic tumors, including non-small cell lung cancer and breast cancer, in phases 1/2 clinical trials.
The drug showed good safety and efficacy in patients during the trials.
The pharmaceutical company's shares dropped 4% during the afternoon trade.